TDC-Exo, a DC-secreted exosome stimulated by tumor antigen carrying MHC-antigen complexes and CD86, was developed as the “CAR” portion of CAR-T, activating T cells and cooperating with anti-CD3 and anti-EGFR and immune checkpoint inhibitory antibodies anti-PD-L1, further enhancing the efficacy of the CAR-T cell therapy mimetic platform for solid tumor treatment (193). This evidence concerns the gene CD86 and neoplasm.